Testing for Early Diagnosis of Alzheimer’s Disease

home / insights / testing-for-early-diagnosis-of-alzheimer-s-disease

Alireza Atri, MD, PhD, discusses the many methods of testing and forming a diagnosis for patients with Alzheimer’s disease, highlighting the recent FDA approval of aducanumab and its impact.

The Pathophysiology of Alzheimer’s Disease

EP. 1: The Pathophysiology of Alzheimer’s Disease

Alireza Atri, MD, PhD
January 25th 2022
Video

Alireza Atri, MD, PhD, describes the pathophysiology of Alzheimer’s disease (AD).

Common Screening Tools for AD and Their Importance

EP. 2: Common Screening Tools for AD and Their Importance

January 25th 2022
Video

Dr Atri lists the common screening tools used to form an AD diagnosis.

Biomarker Testing and its Role in an AD Diagnosis

EP. 3: Biomarker Testing and its Role in an AD Diagnosis

February 1st 2022
Video

An expert explains the role biomarker testing plays when diagnosing a patient with AD.

Aducanumab’s FDA Approval to Treat AD

EP. 4: Aducanumab’s FDA Approval to Treat AD

February 1st 2022
Video

Alireza Atri, MD, PhD, discusses aducanumab’s recent FDA approval for the treatment of AD.

Diagnostic Evaluation for Using Aducanumab in Patients With AD

EP. 5: Diagnostic Evaluation for Using Aducanumab in Patients With AD

February 8th 2022
Video

Dr Atri explains how aducanumab plays a role in diagnostic evaluations for patients with AD.

Diagnostic Evaluations Continued

EP. 6: Diagnostic Evaluations Continued

February 8th 2022
Video

Dr Atri continues his discussion on aducanumab and AD diagnostic evaluations.

The Importance of Different Tests When Caring For Patients With AD

EP. 7: The Importance of Different Tests When Caring For Patients With AD

February 8th 2022
Video

Alireza Atri, MD, PhD, concludes with a discussion on how different testing methods impact the care of patients with AD.

© 2023 MJH Life Sciences

All rights reserved.